Clinical trials: Cerebral Vascular Disorder
Ischemic Stroke
Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)
To determine the revascularization rate of the CE-marked Trevo device in large vessel occlusions in ischemic stroke patients. Revascularization, defined as at least TICI 2a in the vascular territory treated at end of the neuro…
- Trial name
- TREVO (NCT01088672)
- Testing
- Mechanical Thrombectomy
- Where
- 7 sites in Austria, Germany and 2 more
- Volunteers
- 60 people
- Sponsor
- Stryker Neurovascular
Carotid Artery Disease
CAPTURE 2 Post-Marketing Registry
The purposes of the registry are: 1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide…
- Trial name
- CAPTURE 2 (NCT00302237)
- Testing
- RX ACCULINK, RX ACCUNET Embolic Protection System
- Where
- United States
- Volunteers
- 6,426 people
- Sponsor
- Abbott Medical Devices
Pain, Pain Syndrome
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06072001
- Testing
- Adezunap (AP707)
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Intracranial Aneurysm
Neuroform Atlas Stent for Intracranial Aneurysm Treatment
The primary objective of this study is to demonstrate effectiveness and safety of the NeuroForm Atlas stent system for use in patients requiring stent assisted intracranial aneurysm treatment.
- Trial name
- ATLAS EU PMCF (NCT02783339)
- Where
- 11 sites in France, Germany and 1 more
- Volunteers
- 105 people
- Sponsor
- Stryker Neurovascular
Carotid Artery Stenosis
Prospective Single Arm CAS - ROADSAVER Study
Approximately 2000 patients eligible for elective treatment with a Carotid Stent according to hospital routine practice in centers across Europe will be enrolled in the study.
- Trial name
- ROADSAVER (NCT03504228)
- Testing
- Roadsaver
- Where
- 57 sites in Belgium, Czechia and 11 more
- Volunteers
- 1,967 people
- Sponsor
- Terumo Europe N.V.
Lupus Nephritis, Immunoglobulin A Nephropathy
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis …
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- RUBY-3 (NCT05732402)
- Testing
- Povetacicept
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 72 people
- Sponsor
- Alpine Immune Sciences, Inc.
Acute Ischemic Stroke
Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
The primary objective of the study is to confirm the efficacy of compound Edaravone Injection via intravenous infusion every 12 hours in the patients with Acute Ischemic Stroke(AIS) in a double-blind, active-controlled manner.
- Trial name
- NCT04984577
- Testing
- Compound Edaravone Injection-Low dose, Compound Edaravone Injection-High dose, Edaravone Injection
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
Ischemic Stroke, Chronic Stroke
Investigation of Neural Stem Cells in Ischemic Stroke
A study of stereotactic, intracerebral injection of CTX0E03 neural stem cells into patients with moderate to moderately severe disability as a result of an ischemic stroke.
- Conditions
- Ischemic Stroke, Chronic Stroke, Hemiparesis, Arm Paralysis
- Trial name
- PISCES III (NCT03629275)
- Testing
- CTX0E03 Drug Product and delivery device
- Where
- 23 sites in United States
- Volunteers
- 15 people
- Sponsor
- ReNeuron Limited
Ischemic Stroke
Electric Field Navigated 1hz Rtms for Post-stroke Motor Recovery Trial
A prospective, multi-center, randomized, sham-controlled, blinded study combining active Nexstim NBS-guided 1Hz rTMS or sham-rTMS targeting the healthy hemisphere with standardized task oriented rehabilitation will be conducted…
- Trial name
- E-FIT (NCT03010462)
- Testing
- Nexstim NBS guided active rTMS
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Nexstim Ltd
Ischemic Stroke
Phase 2 Study of TXA127 in Post-ischemic Stroke Patients
This is a 50-patient, Phase 2, double-blind, randomized, placebo-controlled, hybrid decentralized study to evaluate the safety and efficacy of daily subcutaneous (SC) injection of TXA127 in post-ischemic stroke patients.
- Trial name
- NCT06135103
- Testing
- talfirastide
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Constant Therapeutics LLC
Pseudobulbar Affect (PBA), Stroke
Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)
The objectives of the study are to evaluate the safety, tolerability, and effectiveness of NUEDEXTA capsules containing 20 mg DM (Dextromethorphan)/10 mg Q (Quinidine) for treatment of Pseudobulbar Affect (PBA) in patients with…
- Conditions
- Pseudobulbar Affect (PBA), Stroke, Dementia, Traumatic Brain Injury (TBI)
- Trial name
- PRISM II (NCT01799941)
- Testing
- Nuedexta (DM 20 mg/Q 10 mg)
- Where
- United States
- Volunteers
- 367 people
- Sponsor
- Avanir Pharmaceuticals
Ischemic Stroke
Percutaneous Recanalization in Ischemic Stroke Management (PRIISM): A Feasibility Clinical Study
The primary study objective is to assess the feasibility of using the MindFrame System to safely and effectively restore blood flow in a thrombotic neurovascular occlusion in patients experiencing an ischemic stroke.
- Trial name
- PRIISM (NCT00810095)
- Testing
- MindFrame System
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- MindFrame, Inc.
Acute Ischemic Stroke
Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness
This study investigates the clinical practices, safety and effectiveness of Cerebrolysin in routine treatment of patients with moderate to severe neurological deficits after acute ischemic stroke.
- Trial name
- C-REGS2 (NCT03480698)
- Testing
- Cerebrolysin
- Where
- 8 sites in Austria
- Volunteers
- 1,851 people
- Sponsor
- Ever Neuro Pharma GmbH
Acute Ischemic Stroke
Study to Assess PK, Safety and Tolerability in Healthy Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of QHRD106 in Chinese healthy subjects with single and multiple doses.
- Trial name
- NCT06380699
- Testing
- QHRD106 Injection, Human Urinary Kallidinogenase
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.
Stroke
"Evaluation Of ALBA® Device for Upper Extremity Motor Function In Adults With Subacute And Chronic Acquired Brain Injury"
As part of the rehabilitation techniques, robotic equipment has been introduced for the rehabilitation of the upper extremity with promising results.
- Trial name
- NCT05824416
- Testing
- Experimental: ALBA, Conventional Therapy
- Where
- Chile
- Volunteers
- 32 people
- Sponsor
- uMov
Fabry Disease
Open-Label Phase 3 Long-Term Safety Study of Migalastat
This was a long-term, open-label study of migalastat (123 milligrams [mg] of migalastat [equivalent to 150 mg of migalastat hydrochloride]) (migalastat) in participants with Fabry disease who completed treatment in a previous…
- Trial name
- AT1001-041 (NCT01458119)
- Testing
- migalastat hydrochloride
- Where
- 25 sites in United States, Argentina and 11 more
- Volunteers
- 85 people
- Sponsor
- Amicus Therapeutics
Fabry's Disease
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
This Phase 4 study will evaluate the safety and tolerability of Fabrazyme at current approved dose with increases in the infusion rate and reduced infusion volume.
- Trial name
- SHORTEN (NCT06019728)
- Testing
- AGALSIDASE BETA (GZ419828), Acetaminophen, Diphenhydramine
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- Sanofi
Acute Ischemic Stroke
A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
This is a multicenter, double-blind, single-dose, randomized, and placebo-controlled prospective Phase IIa clinical study, designed to evaluate LT3001 drug product versus placebo/control in subjects with AIS.
- Trial name
- NCT04091945
- Testing
- LT3001 Drug Product
- Where
- 10 sites in United States, Taiwan
- Volunteers
- 24 people
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Carotid Artery Disease
Carotid Revascularization With ev3 Arterial Technology Evolution (CREATE) Trial
Evaluate the safety and efficacy of the Protege Stent and Spider Device in the treatment of common and/or internal carotid artery stenoses for subjects that are high risk for carotid endarterectomy.
- Trial name
- CREATE (NCT00619775)
- Testing
- PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device
- Where
- 31 sites in United States
- Volunteers
- 419 people
- Sponsor
- Medtronic Endovascular
Fabry Disease
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease
Study to evaluate the safety, tolerability, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.
- Trial name
- NCT00304512
- Testing
- migalastat HCl
- Where
- 6 sites in United States, Australia and 4 more
- Volunteers
- 9 people
- Sponsor
- Amicus Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.